Template:Dgfn2015 Mo 7:00 PCSK9
(Difference between revisions)
Ossip Groth (Talk | contribs) |
Ossip Groth (Talk | contribs) m (→Was kommt nach den Statinen ? Aktuelles zu PCSK9 Antikörpern (König-W)) |
||
| Line 65: | Line 65: | ||
{{tp|p=25082583|t=Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials |pdf=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(14)02704-1|usr=|}} | {{tp|p=25082583|t=Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials |pdf=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(14)02704-1|usr=|}} | ||
| − | {{utp|p=20102893|t=Meta-analysis of comparative efficacy of | ||